Penumbra - PEN Stock Forecast, Price & News

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Penumbra Stock Up 1.4 %

Penumbra stock traded up $2.27 during mid-day trading on Monday, hitting $169.10. The company had a trading volume of 627,791 shares, compared to its average volume of 301,882. The stock has a market cap of $6.37 billion, a price-to-earnings ratio of -325.19 and a beta of 0.73. Penumbra has a 1 year low of $114.86 and a 1 year high of $293.20. The company has a quick ratio of 2.90, a current ratio of 4.93 and a debt-to-equity ratio of 0.03. The business has a fifty day moving average of $132.45 and a 200 day moving average of $173.66.

Penumbra (NYSE:PEN - Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.07. The company had revenue of $208.30 million for the quarter, compared to analyst estimates of $206.24 million. Penumbra had a negative net margin of 2.40% and a positive return on equity of 0.97%. The firm's revenue was up 13.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.21 earnings per share. On average, sell-side analysts expect that Penumbra will post 0.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Truist Financial reduced their price target on shares of Penumbra to $180.00 in a research report on Friday, July 22nd. Deutsche Bank Aktiengesellschaft cut their target price on shares of Penumbra from $250.00 to $163.00 in a research note on Thursday, July 21st. TheStreet lowered shares of Penumbra from a "c-" rating to a "d+" rating in a research note on Tuesday, July 12th. Citigroup cut their target price on shares of Penumbra from $280.00 to $220.00 in a research note on Tuesday, May 17th. Finally, Wells Fargo & Company cut their target price on shares of Penumbra from $321.00 to $265.00 in a research note on Wednesday, May 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $218.78.

Insider Transactions at Penumbra

In other news, Director Thomas Wilder sold 248 shares of the firm's stock in a transaction that occurred on Tuesday, July 5th. The shares were sold at an average price of $123.64, for a total transaction of $30,662.72. Following the transaction, the director now directly owns 462 shares in the company, valued at $57,121.68. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 451 shares of company stock worth $57,968. Insiders own 5.50% of the company's stock.